Novoseven RT 1 MG vials
Ended Awarded
- Contract number
- SPE2DB25FPRA6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,632
Award facts
- Contract value 100% obligated
- $19,631.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $19,631.64 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on July 30, 2025, for the supply of Novoseven RT 1 mg vials. This delivery order, which must be completed by July 31, 2025, was issued without set-aside designation and represents performance at DMS Pharmaceutical Group's Park Ridge location. The award falls under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which authorizes the agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products supporting Department of Defense military health facilities worldwide.
Novoseven RT is a recombinant activated Factor VII (eptacog alfa) used in hemostasis management for patients with bleeding disorders. This delivery order reflects the DLA's ongoing procurement of specialized pharmaceutical products through DMS Pharmaceutical Group's established supply chain capabilities. As a critical pharmaceutical supplier to federal healthcare systems, DMS Pharmaceutical Group has demonstrated consistent performance in delivering branded and generic prescription drugs, biologics, and medical consumables to military and federal healthcare facilities. The company's federal contract portfolio reflects its significant role in supporting the Defense Logistics Agency's pharmaceutical distribution mission across the Department of Defense healthcare network.
Quick answers
Who was awarded contract SPE2DB25FPRA6?
SPE2DB25FPRA6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 30, 2025.
How much is contract SPE2DB25FPRA6 worth?
The government has obligated $19,632 on SPE2DB25FPRA6.
Is contract SPE2DB25FPRA6 an order under another contract?
Yes. SPE2DB25FPRA6 is a delivery order under SPE2DB20D9127, an indefinite delivery contract.
Was contract SPE2DB25FPRA6 competed?
The extent of competition for SPE2DB25FPRA6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award